

REMARKS/ARGUMENTS

The Examiner has required restriction in the above-identified application, as follows:

Group I: Claim 9 and Claims 1-8, 20-26 when A is CH=CH, V-W is C=C, drawn to dibenzo[a,d]cycloheptenlidene piperidines and their composition;

Group II: Claim 10 not encompassed by Claim 9, and Claims 1-8, 20-26 when A is S, V-W is C=C, drawn to dibenzo[a,d]thiopyranylidene piperidines and their composition;

Group III: Claims 1-8, 20-26 remaining compounds, drawn to various core structure compounds;

Group IV: Claims 11-18, drawn to method of treating diseases; and

Group V: Claim 19, drawn to method of antagonizing N-type calcium channels.

Applicants have elected, without traverse, Group II, as the group for prosecution.

Although the present election has been made without traverse, Applicants note that the present application a continuation or "by-pass" application and, accordingly, the PCT rules of unity of invention are inapplicable.

Applicants submit that the present application is now ready for examination on the merits, and early notice of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Stephen G. Baxter
Registration No. 32,884

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)